Zacks Investment ResearchFri, 05 Jun 2026 19:16:14 GMTHere's Why You Should Retain Glaukos Stock in Your Portfolio NowGKOS+2.63%
Zacks Investment ResearchThu, 30 Apr 2026 15:55:14 GMTGlaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue OutlookGKOS+2.63%
Seeking AlphaThu, 30 Apr 2026 03:21:32 GMTGlaukos Corporation (GKOS) Q1 2026 Earnings Call TranscriptGKOS+2.63%
Zacks Investment ResearchThu, 30 Apr 2026 02:00:22 GMTGlaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesGKOS+2.63%
Zacks Investment ResearchWed, 29 Apr 2026 23:41:50 GMTGlaukos (GKOS) Reports Q1 Loss, Tops Revenue EstimatesGKOS+2.63%
Zacks Investment ResearchThu, 16 Apr 2026 15:26:05 GMTGlaukos Wins Permanent J-Code for Epioxa Keratoconus TherapyGKOS+2.63%
Zacks Investment ResearchFri, 20 Mar 2026 14:35:34 GMTGlaukos Launches Epioxa, Boosts Growth in Corneal TreatmentsGKOS+2.63%
Zacks Investment ResearchThu, 19 Mar 2026 16:31:21 GMTWhy Is Glaukos (GKOS) Down 14.7% Since Last Earnings Report?GKOS+2.63%
